Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Myeloid Differentiation in Myelodysplastic Neoplasms and Leukemic Cells: Role of Azacitidine and Direct Contact with Mesenchymal Stromal Cells

Eleonora Ceneri, Irene Casalin, Alessia De Stefano, Alessandra Cappellini, Lucio Cocco, Stefano Ratti, Lucia Manzoli, Michele Cavo, Miriam Fogli, Sarah Parisi, Stefania Paolini, Marilena Ciciarello, Antonio Curti, Carlo Finelli, Matilde Yung Follo

Blood (2024) 144 (Supplement 1): 6688.

https://doi.org/10.1182/blood-2024-204876

Published: 2024

Journal Articles

Investigating Phosphoinositide-Related and Apoptotic Pathways in Azacitidine and Venetoclax Combination Therapy in Higher-Risk Myelodysplastic Neoplasms and Leukemic Cell Lines

Irene Casalin, Eleonora Ceneri, Alessia De Stefano, Alessandra Cappellini, Andrea Pellagatti, Jacqueline Boultwood, Michele Cavo, Stefano Ratti, Lucia Manzoli, Lucio Cocco, Anna Ferrari, Giorgia Simonetti, Giovanni Martinelli, Miriam Fogli, Stefania Paolini, Sarah Parisi, Antonio Curti, Carlo Finelli, Matilde Yung Follo

Blood (2024) 144 (Supplement 1): 6686.

https://doi.org/10.1182/blood-2024-200842

Published: 2024

Journal Articles

Bone Marrow Microenvironment As a Potential Key Regulator of Hematopoietic Cells Stemness in Myelodysplastic Syndromes (MDS)

Irene Casalin, Alessia De Stefano, Alessandra Cappellini, Eleonora Ceneri, Martina Lops, Andrea Pellagatti, Jacqueline Boultwood, Michele Cavo, Stefano Ratti, Lucia Manzoli, Lucio Cocco, Marilena Ciciarello, Miriam Fogli, Stefania Paolini, Sarah Parisi, Antonio Curti, Carlo Finelli, Matilde Yung Follo

Blood (2023) 142 (Supplement 1): 6463.

https://doi.org/10.1182/blood-2023-179914

Published: 2023

Journal Articles

Venetoclax Rapidly and Strongly Enhances the Phospholipase C Response to Azacitidine Therapy in Myelodysplastic Syndromes

Matilde Y Follo, Alessia De Stefano, Sara Mongiorgi, Irene Casalin, Alessandra Cappellini, Stefano Ratti, Andrea Pellagatti, Miriam Fogli, Michele Cavo, Lucia Manzoli, Lucio Cocco, Jacqueline Boultwood, Sarah Parisi, Stefania Paolini, Antonio Curti, Carlo Finelli

Blood (2022) 140 (Supplement 1): 6905–6906.

https://doi.org/10.1182/blood-2022-163628

Published: 2022

Journal Articles

Role of Mir-192-5p during Response to Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

Matilde Y Follo, Alessia De Stefano, Sara Mongiorgi, Valentina Indio, Annalisa Astolfi, Stefano Ratti, Andrea Pellagatti, Miriam Fogli, Andrea Pession, Michele Cavo, Lucia Manzoli, Lucio Cocco, Jacqueline Boultwood, Sarah Parisi, Stefania Paolini, Carlo Finelli

Blood (2021) 138 (Supplement 1): 3673.

https://doi.org/10.1182/blood-2021-149183

Published: 2021

Journal Articles

Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses

Blood (2020) 136 (Supplement 1): 45.

https://doi.org/10.1182/blood-2020-138371

Published: 2020

Journal Articles

Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Alessia De Stefano, BSc, Valentina Indio, PhD, Annalisa Astolfi, PhD, Andrea Pellagatti, Stefano Ratti, MD, Miriam Fogli, PhD, Sarah Parisi, MDPhD, Andrea Pession, Michele Cavo, Lucia Manzoli, MD, Lucio Cocco, MD, Jacqueline Boultwood, Carlo Finelli

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-136942

Published: 2020

Journal Articles

Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Blood (2018) 132 (Supplement 1): 4347.

https://doi.org/10.1182/blood-2018-99-112062

Published: 2018

Journal Articles

Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study

Blood (2018) 132 (Supplement 1): 4365.

https://doi.org/10.1182/blood-2018-99-117714

Published: 2018

Journal Articles

Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR 4.0 , MR 4.5 And MR 5.0 ) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR)

Blood (2016) 128 (22): 3096.

https://doi.org/10.1182/blood.V128.22.3096.3096

Published: 2016

Journal Articles

A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line

Blood (2016) 128 (22): 3076.

https://doi.org/10.1182/blood.V128.22.3076.3076

Published: 2016

Journal Articles

Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML

Domenico Russo, MD, Giovanni Martinelli, Michele Malagola, Valeria Cancelli, Cristina Skert, MD, Simona Soverini, PhD, Ilaria Iacobucci, PhD, Diamante Turri, Salvatore Mirto, MD, Marco Gobbi, MD, Ivana Pierri, MD, Umberto Vitolo, Patrizia Pregno, MD, Miriam Fogli, Nicoletta Testoni, Antonio De Vivo, Fausto Castagnetti, Enrica Morra, Ester Pungolino, MD, Francesco Di Raimondo, MD, Fabio Stagno, MD PhD, Giuliana Alimena, Massimo Breccia, MD, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, MD, Giuseppe Saglio, MD, Giovanna Rege Cambrin, Giuseppe Visani, MD, Giuseppina Nicolini, Paolo de Fabritiis, MD, Elisabetta Abruzzese, MD, Renato Fanin, MD, Mario Tiribelli, MD, Piero Galieni, MD, Catia Bigazzi, Giorgina Specchia, MD, Emanuele Angelucci, Emilio Usala, MD, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, MD PhD, Monia Lunghi, MD, Francesco Lauria, MD, Monica Bocchia, MD, Francesco Rodeghiero, Anna D'Emilio, Alberto Bosi, MD, Valeria Santini, Giovanni Quarta, MD, Mariella Girasoli, Giuseppe Fioritoni, MD, Roberto Di Lorenzo, Bruno Mario Cesana, Gianantonio Rosti

Blood (2014) 124 (21): 1794.

https://doi.org/10.1182/blood.V124.21.1794.1794

Published: 2014

Journal Articles

Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.

Blood (2012) 120 (21): 2601.

https://doi.org/10.1182/blood.V120.21.2601.2601

Published: 2012

Journal Articles

Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year

Domenico Russo, Michele Baccarani, MD, Giovanni Martinelli, MD, Chiara Colombi, Michele Malagola, Cristina Skert, MD, Simona Soverini, Ilaria Iacobucci, PhD, Diamante Turri, MD, Salvatore Mirto, Marco Gobbi, MD, Ivana Pierri, Umberto Vitolo, MD, Patrizia Pregno, MD, Miriam Fogli, Nicoletta Testoni, Antonio De Vivo, Fausto Castagnetti, Enrica Morra, Ester Pungolino, Francesco Di Raimondo, MD, Fabio Stagno, Giuliana Alimena, Massimo Breccia, Francesco Nobile, MD, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, MD, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Giorgina Specchia, Emanuele Angelucci, Emilio Usala, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, Monia Lunghi, M.D., Francesco Lauria, MD, Monica Bocchia, Francesco Rodeghiero, MD, Anna D'Emilio, Alberto Bosi, MD, Valeria Santini, MD, Giovanni Quarta, Mariella Girasoli, Giuseppe Fioritoni, MD, Roberto Di Lorenzo, Bruno Cesana, Gianantonio Rosti, MD

Blood (2011) 118 (21): 1682.

https://doi.org/10.1182/blood.V118.21.1682.1682

Published: 2011

Journal Articles

Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509

Domenico Russo, Giuliana Alimena, Chiara Colombi, Massimo Breccia, Simona Soverini, Ilaria Iacobucci, PhD, Federica Cattina, MD, Giovanni Martinelli, MD, Nicoletta Testoni, Anna Marina Liberati, Viviana Appolloni, Mario Tiribelli, Renato Fanin, Felicetto Ferrara, MD, Mario Annunziata, MD, Elena Trabacchi, Daniele Vallisa, MD, Antonio De Vivo, Fausto Castagnetti, Miriam Fogli, Sandra Durante, Francesco Di Raimondo, MD, Fabio Stagno, A. M. Carella, G. Pica, Alessandra Iurlo, M.D., Tommaso Radice, Patrizia Pregno, MD, Umberto Vitolo, MD, Elisabetta Abruzzese, Paolo de Fabritiis, Maurizio Longinotti, MD, Simonetta Pardini, Caterina Musolino, MD, Sabina Russo, Marco Gobbi, MD, Ivana Pierri, Gianluca Gaidano, Monia Lunghi, M.D., Giuseppe Visani, Sara Barulli, Mario Cazzola, Serena Merante, Cristina Skert, MD, Michele Malagola, Gianantonio Rosti, MD, Michele Baccarani, MD

Blood (2011) 118 (21): 786.

https://doi.org/10.1182/blood.V118.21.786.786

Published: 2011

Journal Articles

One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.

Domenico Russo, Giovanni Martinelli, Michele Malagola, MD, Chiara Colombi, Giantonio Rosti, Marilina Amabile, Miriam Fogli, Diamante Turri, Salvatore Mirto, Marco Gobbi, Ivana Pierri, Umberto Vitolo, Patrizia Pregno, Enrica Morra, Ester Pungolino, Francesco Di Raimondo, Fabio Stagno, MD, Robin Foà, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Giorgina Specchia, Vincenzo Liso, MD, Emanuele Angelucci, Emilio Usala, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, Monia Lunghi, Francesco Lauria, Monica Bocchia, Francesco Rodeghiero, Anna D'Emilio, Alberto Bosi, Valeria Santini, Giovanni Quarta, Mariella Girasoli, Giuseppe Fioritoni, Roberto Di Lorenzo, Nicoletta Testoni, Antonio De Vivo, Simona Soverini, Ilaria Iacobucci, Michele Baccarani, Michele Baccarani

Blood (2010) 116 (21): 3412.

https://doi.org/10.1182/blood.V116.21.3412.3412

Published: 2010

Journal Articles

Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34 − cell population with intrinsic resistance to imatinib

Roberto M. Lemoli, Valentina Salvestrini, Elisa Bianchi, Francesco Bertolini, Miriam Fogli, Marilina Amabile, Agostino Tafuri, Simona Salati, Roberta Zini, Nicoletta Testoni, Cristina Rabascio, Lara Rossi, Ines Martin-Padura, Fausto Castagnetti, Paola Marighetti, Giovanni Martinelli, Michele Baccarani, Sergio Ferrari, Rossella Manfredini

Blood (2009) 114 (25): 5191–5200.

https://doi.org/10.1182/blood-2008-08-176016

Published: 2009

Includes: Supplemental data

Journal Articles

Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.

Domenico Russo, Gianantonio Rosti, Giovanni Martinelli, Michele Malagola, Salvatore Mirto, Diamante Turri, Marco Gobbi, Ivana Pierri, Umberto Vitolo, MD, Patrizia Pregno, Francesco Di Raimondo, M.D., Fabio Stagno, Robin Foà, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, MD, Tamara Intermesoli, Giuseppe Saglio, MD, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Vincenzo Liso, Giorgina Specchia, Emanuele Angelucci, Emilio Usala, Caterina Musolino, Sabina Russo, Gianluca Gaidano, MD, Monia Lunghi, Francesco Lauria, MD, Monica Bocchia, Francesco Rodeghiero, MD, Anna D'Emilio, MD, Giovanni Quarta, Mariella Girasoli, Alberto Bosi, Valeria Santini, Giuseppe Fioritoni, Roberto Di Lorenzo, Chiara Colombi, Miriam Fogli, Marilina Amabile, Nicoletta Testoni, Antonio De Vivo, Michele Baccarani

Blood (2009) 114 (22): 860.

https://doi.org/10.1182/blood.V114.22.860.860

Published: 2009

Journal Articles

Molecular and Functional Analysis of Stem Cell Compartment of Chronic Myelogenous Leukemia Reveals the Presence of a CD34 − cell Population with Intrinsic Resistance to IMATINIB Treatment

Valentina Salvestrini, Rossella Manfredini, MD, Miriam Fogli, Elisa Bianchi, Simona Salati, PhD, Marilina Amabile, Francesco Bertolini, Agostino Tafuri, Roberta Zini, Nicoletta Testoni, Cristina Rabascio, Lara Rossi, Giovanni Martinelli, Michele Baccarani, MD, Sergio Ferrari, Roberto M Lemoli

Blood (2008) 112 (11): 4221.

https://doi.org/10.1182/blood.V112.11.4221.4221

Published: 2008

Journal Articles

Phase II Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy

Domenico Russo, Michele Malagola, Chiara Colombi, Massimo Breccia, Miriam Fogli, Piero Galieni, Giovanni Martinelli, Salvatore Mirto, Umberto Vitolo, Elisabetta Abruzzese, Giuliana Alimena, Monica Bocchia, Angelo Michele Carella, Fabrizio Pane, Gianantonio Rosti, Giuseppe Saglio, Giorgina Specchia, Michele Baccarani

Blood (2008) 112 (11): 4288.

https://doi.org/10.1182/blood.V112.11.4288.4288

Published: 2008

NARROW

Myeloid Differentiation in Myelodysplastic Neoplasms and Leukemic Cells: Role of Azacitidine and Direct Contact with Mesenchymal Stromal Cells

Investigating Phosphoinositide-Related and Apoptotic Pathways in Azacitidine and Venetoclax Combination Therapy in Higher-Risk Myelodysplastic Neoplasms and Leukemic Cell Lines

Bone Marrow Microenvironment As a Potential Key Regulator of Hematopoietic Cells Stemness in Myelodysplastic Syndromes (MDS)

Venetoclax Rapidly and Strongly Enhances the Phospholipase C Response to Azacitidine Therapy in Myelodysplastic Syndromes

Role of Mir-192-5p during Response to Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses

Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study

Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR 4.0 , MR 4.5 And MR 5.0 ) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR)

A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line

Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML

Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.

Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year

Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509

One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.

Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34 − cell population with intrinsic resistance to imatinib

Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.

Molecular and Functional Analysis of Stem Cell Compartment of Chronic Myelogenous Leukemia Reveals the Presence of a CD34 − cell Population with Intrinsic Resistance to IMATINIB Treatment

Phase II Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only